Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx-to-OTC switch promotions

This article was originally published in The Tan Sheet

Executive Summary

FDA will address "during the next year" the "difficult regulatory issue" of consumer advertising for drugs that are available both OTC and by prescription for different indications, FDA Policy Development & Coordination Staff Director David Adams told a March 1 Regulatory Affairs Professionals Society meeting in Chicago. Adams explained that there is a "natural tendency" among companies to "promote the relationship between the new OTC product" and the "established prescription product," which can lead to associating "Rx indications with the OTC product." The FDAer suggested that "this undermines the role of the physician in prescribing the Rx product for the Rx indication"
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel